ICCC

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

Wall Street analysts forecast ICCC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ImmuCell Corp revenue for the last quarter amounts to 5.51M USD, decreased -8.41 % YoY.

ImmuCell Corp. EPS for the last quarter amounts to -0.02 USD, decreased -77.78 % YoY.

ImmuCell Corp (ICCC) has 69 emplpoyees as of December 15 2025.

Today ICCC has the market capitalization of 56.17M USD.